Biohaven (BHVN) stock plunges as the FDA declines to approve its lead drug Vyglxia (troriluzole) targeted at spinocerebellar ...
Molecular diagnostics firm BillionToOne raised $273.1 million in its U.S. initial public offering on Wednesday, pricing its shares above its marketed range.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback